PL
NAMS icon

Parkwood LLC’s NewAmsterdam Pharma NAMS Stock Holding History

Parkwood LLC’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,782
Closed -$265K – 116
2024
Q2 		$265K Buy
+13,782
New +$277K 0.03% 113
2023
Q4 		– Sell
-20,209
Closed -$187K – 154
2023
Q3 		$187K Buy
+20,209
New +$219K 0.02% 128

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Parkwood LLC's NAMS Position: Q3 2024 in Review

Parkwood LLC sold out of NewAmsterdam Pharma (NAMS) in Q3 2024, closing a stake of 13,782 shares — an estimated $265K sold.

Parkwood LLC first reported a position in NAMS in Q3 2023 and held it in 2 quarters. The position peaked at $265K in Q2 2024. 100 funds tracked by Wall St. Rank hold NAMS as of Q3 2024.

  • Parkwood LLC reported no remaining NewAmsterdam Pharma position as of Q3 2024 after selling out during the quarter.
  • Parkwood LLC sold 13,782 NewAmsterdam Pharma shares in Q3 2024, an estimated $265K.
  • Parkwood LLC first reported a position in NewAmsterdam Pharma in Q3 2023 and held it in 2 quarters.
  • Parkwood LLC's NewAmsterdam Pharma position peaked at $265K in Q2 2024.
  • 100 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2024.

Based on Parkwood LLC's 13F filing for Q3 2024, filed 14 Nov 2024.